The n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert hypolipidemic effects and prevent development of obesity and insulin resistance in animals fed high-fat diets. We sought to determine the efficacy of alpha-substituted DHA derivatives as lipid-lowering, antiobesity, and antidiabetic agents. C57BL/6 mice were given a corn oil-based high-fat (35% weight/weight) diet (cHF), or cHF with 1.5% of lipids replaced with alpha-methyl DHA ethyl ester (Substance 1), alpha-ethyl DHA ethyl ester (Substance 2), alpha,alpha-di-methyl DHA ethyl ester (Substance 3), or alpha-thioethyl DHA ethyl ester (Substance 4) for 4 months. Plasma markers of glucose and lipid metabolism, glucose tolerance, morphology, tissue lipid content, and gene regulation were characterized. The cHF induced obesity, hyperlipidemia, impairment of glucose homeostasis, and adipose tissue inflammation. Except for Substance 3, all other substances prevented weight gain and Substance 2 exerted the strongest effect (63% of cHF-controls). Glucose intolerance was significantly prevented (~67% of cHF) by both Substance 1 and Substance 2. Moreover, Substance 2 lowered fasting glycemia, plasma insulin, triacylglycerols, and nonesterified fatty acids (73, 9, 47, and 81% of cHF-controls, respectively). Substance 2 reduced accumulation of lipids in liver and skeletal muscle, as well as adipose tissue inflammation associated with obesity. Substance 2 also induced weight loss in dietary obese mice. In contrast to DHA administered either alone or as a component of the EPA/DHA concentrate (replacing 15% of dietary lipids), Substance 2 also reversed established glucose intolerance in obese mice. Thus, Substance 2 represents a novel compound with a promising potential in the treatment of obesity and associated metabolic disturbances.

Department of Adipose Tissue Biology and Center for Applied Genomics Institute of Physiology Academy of Sciences of the Czech Republic Prague Czech Republic

000      

04059naa 2200601 a 4500

001      

bmc11017215

003      

CZ-PrNML

005      

20130617125736.0

008      

110629s2009 xxu e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Rossmeisl, Martin. $7 xx0270807

245    10

$a Prevention and reversal of obesity and glucose intolerance in mice by DHA derivatives / $c M. Rossmeisl, T. Jeleník, Z. Jílková, K. Slámová, V. Kus, M. Hensler, D. Medříková, C. Povýšil, P. Flachs, V. Mohamed-Ali, M. Bryhn, K. Berge, A.K. Holmeide, J. Kopecký

314    __

$a Department of Adipose Tissue Biology and Center for Applied Genomics, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

520    9_

$a The n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert hypolipidemic effects and prevent development of obesity and insulin resistance in animals fed high-fat diets. We sought to determine the efficacy of alpha-substituted DHA derivatives as lipid-lowering, antiobesity, and antidiabetic agents. C57BL/6 mice were given a corn oil-based high-fat (35% weight/weight) diet (cHF), or cHF with 1.5% of lipids replaced with alpha-methyl DHA ethyl ester (Substance 1), alpha-ethyl DHA ethyl ester (Substance 2), alpha,alpha-di-methyl DHA ethyl ester (Substance 3), or alpha-thioethyl DHA ethyl ester (Substance 4) for 4 months. Plasma markers of glucose and lipid metabolism, glucose tolerance, morphology, tissue lipid content, and gene regulation were characterized. The cHF induced obesity, hyperlipidemia, impairment of glucose homeostasis, and adipose tissue inflammation. Except for Substance 3, all other substances prevented weight gain and Substance 2 exerted the strongest effect (63% of cHF-controls). Glucose intolerance was significantly prevented (~67% of cHF) by both Substance 1 and Substance 2. Moreover, Substance 2 lowered fasting glycemia, plasma insulin, triacylglycerols, and nonesterified fatty acids (73, 9, 47, and 81% of cHF-controls, respectively). Substance 2 reduced accumulation of lipids in liver and skeletal muscle, as well as adipose tissue inflammation associated with obesity. Substance 2 also induced weight loss in dietary obese mice. In contrast to DHA administered either alone or as a component of the EPA/DHA concentrate (replacing 15% of dietary lipids), Substance 2 also reversed established glucose intolerance in obese mice. Thus, Substance 2 represents a novel compound with a promising potential in the treatment of obesity and associated metabolic disturbances.

590    __

$a bohemika - dle Pubmed

650    _2

$a zvířata $7 D000818

650    _2

$a dietní tuky $7 D004041

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a kyseliny dokosahexaenové $x terapeutické užití $7 D004281

650    _2

$a energetický příjem $7 D002149

650    _2

$a glukosa $x metabolismus $7 D005947

650    _2

$a porucha glukózové tolerance $x farmakoterapie $x prevence a kontrola $7 D018149

650    _2

$a glukózový toleranční test $7 D005951

650    _2

$a hypolipidemika $x terapeutické užití $7 D000960

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a myši $7 D051379

650    _2

$a myši inbrední C57BL $7 D008810

650    _2

$a obezita $x farmakoterapie $x prevence a kontrola $7 D009765

650    _2

$a polymerázová řetězová reakce $7 D016133

650    _2

$a RNA $x genetika $x izolace a purifikace $7 D012313

650    _2

$a triglyceridy $x metabolismus $7 D014280

650    _2

$a hmotnostní přírůstek $7 D015430

655    _2

$a práce podpořená grantem $7 D013485

700    1#

$a Jeleník, Tomáš. $7 xx0300617

700    1_

$a Macek Jílková, Zuzana, $d 1981- $7 xx0128795

700    1_

$a Slámová, Kristýna $7 xx0125284

700    1#

$a Kus, Vladimír. $7 _AN051187

700    1#

$a Hensler, Michal. $7 _AN044964

700    1_

$a Medříková, Dáša $7 xx0105138

700    1_

$a Povýšil, Ctibor, $d 1943- $7 jn20001103579

700    1#

$a Flachs, Pavel. $7 _AN029338

700    1_

$a Mohamed-Ali, Vidya

700    1_

$a Bryhn, Morten

700    1_

$a Berge, Kjetil

700    1_

$a Holmeide, Anne K.

700    1_

$a Kopecký, Jan, $d 1951- $7 jo20010086901

773    0_

$t Obesity $w MED00150944 $g Roč. 17, č. 5 (2009), s. 1023-1031 $x 1930-7381

910    __

$a ABA008 $b x $y 2

990    __

$a 20110720103247 $b ABA008

991    __

$a 20130617130123 $b ABA008

999    __

$a ok $b bmc $g 864200 $s 727013

BAS    __

$a 3

BMC    __

$a 2009 $x MED00150944 $b 17 $c 5 $d 1023-1031 $i 1930-7381 $m Obesity $n Obesity (Silver Spring)

LZP    __

$a 2011-3B09/BBjvme